A population-based assessment of blood lead levels in relation to inflammation

Environmental Research

Volumn 110, Issue 3, 2010, Pages 272-277

  Songdej, Natthapol ^a   Winters, Paul C ^a   McCabe Jr , Michael J ^a   Wijngaarden, Edwin van ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

C reactive protein; Gender differences; Inflammation; Lead; White blood cell count

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN;

EXPERIMENTAL STUDY; LEAD; OBSERVATIONAL METHOD; PROTEIN; SEX-RELATED DIFFERENCE; TOXICITY;

ADULT; ARTICLE; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; INFLAMMATION; LEAD BLOOD LEVEL; LEAD POISONING; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; LEAD; LEUKOCYTE COUNT; MALE; MIDDLE AGED;

EID: 77649237679     PISSN: 00139351     EISSN: 10960953     Source Type: Journal    
DOI: 10.1016/j.envres.2009.12.008     Document Type: Article

References (67)

1. Ahamed M., and Siddiqui M.K.J. Low level lead exposure and oxidative stress: current opinions. Clin. Chem. Acta 383 (2007) 57-64
2. Allison P.D. Comparing logit and probit coefficients across groups. Sociol. Methods Res. 28 (1999) 186-208
3. Ananth C.V., and Kleinbaum D.G. Regression models for ordinal responses: a review of methods and applications. Int. J. Epidemiol. 26 (1997) 1323-1333
4. Barth A., Schaffer A.W., Osterode W., Winker R., Konnaris C., Valic E., Wolf C., and Rudiger H.W. Reduced cognitive abilities in lead-exposed men. Int. Arch. Occup. Environ. Health. 75 (2002) 394-398
5. Bernier J., Brousseau P., Krzystyniak K., Tryphonas H., and Fournier M. Immunotoxicity of heavy metals in relation to Great Lakes. Environ. Health Perspect. 103 (1995) 23-34
6. Blay J.Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., Mercatello A., Ravault A., Tourani J.M., Moskovtchenko J.F., Philip T., and Favrot M. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 52 (1992) 3317-3322
7. Bravo Y., Quiroz Y., Ferrebuz A., Vaziri N.D., and Rodríguez-Iturbe B. Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. Am. J. Physiol. - Renal Physiol. 293 (2007) F616-F623
8. Canfield R.L., Henderson C.R.J., Cory-Slechta D.A., Cox C., Jusko T.A., and Lanphear B.P. Intellectual impairment in children with blood lead concentrations below 10 μg per deciliter. N. Engl. J. Med. 348 (2003) 1517-1526
9. Centers for Disease Control and Prevention (CDC). 2007. National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey, 2007-2008 Overview. National Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention,〈http://www.cdc.gov/nchs/data/nhanes/nhanes_07_08/overviewbrochure_08.pdf.〉
10. Centers for Disease Control and Prevention (CDCa). 2004. National Center for Health Statistics (NCHS). Laboratory Procedure Manual (Lead, Cadmium, and Mercury). National Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/l06_c_met_pb_cd_hg.pdf.
11. Centers for Disease Control and Prevention (CDCb). 2004. National Center for Health Statistics (NCHS). Anthropometry Procedures Manual. National Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/BM.pdf.
12. Centers for Disease Control and Prevention (CDC). 2001. National Center for Health Statistics (NCHS). Laboratory Procedure Manual (Lead and Cadmium). National Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, http://www.cdc.gov/nchs/data/nhanes/frequency/lab06_met_lead_and_cadmium.pdf.
13. Centers for Disease Control and Prevention (CDC). 2000. National Center for Health Statistics (NCHS). Laboratory Procedure Manual (C-Reactive Protein). National Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/l11_c_met_c_reactive_protein.pdf.
14. Centers for Disease Control and Prevention (CDCa). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey, 1999-2008 Survey Content. National Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, http://www.cdc.gov/nchs/data/nhanes/survey_content_99_08.pdf.
15. Centers for Disease Control and Prevention (CDCb). National Center for Health Statistics (NCHS). Laboratory Procedure Manual (Fibrinogen). National Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, http://www.cdc.gov/nchs/data/nhanes/nhanes_01_02/l11_b_met_fibrinogen.pdf.
16. Centers for Disease Control and Prevention (CDCc). National Center for Health Statistics (NCHS). Laboratory Procedure Manual (Complete Blood Count). National Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/l25_c_met_complete_blood_count.pdf.
17. Dahl M., Tybjærg-Hansen A., Vestbo J., Lange P., and Nordestgaard B.G. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164 (2001) 1008-1011
18. Dahl M., Vestbo J., Lange P., Bojesen S.E., Tybjærg-Hansen A., and Nordestgaard B.G. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175 (2007) 250-255
19. Erlinger T.P., Platz E.A., Rifai N., and Helzlsouer K.J. C-reactive protein and the risk of incident colorectal cancer. JAMA 291 (2004) 585-590
20. Fuller G.M., and Zhang Z. Transcriptional control mechanism of fibrinogen gene expression. Ann. N. Y. Acad. Sci. 936 (2001) 469-479
21. Hage F.G., and Szalai A.J. C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovascular disease risk. J. Am. Coll. Cardiol. 50 (2007) 1115-1122
22. Harris T.B., Ferrucci L., Tracy R.P., Corti M.C., Wacholder S., Ettinger W.H., Heimovitz H., Cohen H.J., and Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am. J. Med. 106 (1999) 506-512
23. Hefler L.A., Concin N., Hofstetter G., Marth C., Mustea A., Sehouli J., Zeillinger R., Leipold H., Lass H., Grimm C., Tempfer C.B., and Reinthaller A. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin. Cancer Res. 14 (2008) 710-714
24. Heo Y., Lee W.T., and Lawrence D.A. Differential effects of lead and cAMP on development and activities of Th1 and Th2 lymphocytes. Toxicol. Sci. 43 (1998) 172-185
25. Hu H., Shih R., Rothenberg S., and Schwartz B.S. The epidemiology of lead toxicity in adults: measuring dose and consideration of other methodologic issues. Environ. Health Perspect. 115 (2007) 455-462
26. Iavicoli I., Carelli G., Stanek III E.J., Castellino N., and Calabrese EJ. Below background levels of blood lead impact cytokine levels in male and female mice. Toxicol. Appl. Pharmacol. 210 1-2 (2006) 94-99
27. Keitt S.K., Fagan T.F., and Marts S.A. Understanding sex differences in environmental health: a thought leaders' roundtable. Environ. Health Perspect. 112 (2004) 604-609
28. Kim J.H., Lee K., Yoo D.H., Kang D., Cho S., and Hong Y. GSTM1 and TNF-alpha gene polymorphisms and relations between blood lead and inflammatory markers in a non-occupational population. Mut. Res. 629 (2007) 32-39
29. Kishikawa H., and Lawrence D.A. Differential production of interleukin-6 in the brain and spleen of mice treated with lipopolysaccharide in the presence and absence of lead. J. Toxicol. Environ. Health 53 (1998) 357-373
30. Koenig W., Khuseyinova N., Baumert J., and Meisinger C. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA augsburg cohort study, 1984-1998. Clin. Chem. 54 (2008) 335-342
31. Kosnett M.J., Wedeen R.P., Rothenberg S.J., Hipkins K.L., Materna B.L., Schwartz B.S., Hu H., and Woolf A. Recommendations for medical management of adult lead exposure. Environ. Health Perspect. 115 (2007) 463-471
32. Lee C.D., Folsom A.R., Nieto F.J., Chambless L.E., Shahar E., and Wolfe D.A. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and white men and women: atherosclerosis risk in communities study. Am. J. Epidemiol. 154 (2001) 758-764
33. Lee D., and Jacobs D.R.J. Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis 178 (2005) 327-330
34. Lee D., Lim J., Song K., Boo Y., and Jacobs D.R.J. Graded associations of blood lead and urinary cadmium concentrations with oxidative-stress-related markers in the US population: results from the third national health and nutrition examination survey. Environ. Health Perspect. 114 (2006) 350-354
35. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 169 (2003) 203-214
36. Margolis K.L., Rodabough R.J., Thomson C.A., Lopez A.M., and McTiernan A. Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Arch. Intern. Med. 167 (2007) 1837-1844
37. McSorley M.A., Alberg A.J., Allen D.S., Allen N.E., Brinton L.A., Dorgan J.F., Pollak M., Tao Y., and Helzlsouer K.J. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet. Gynecol. 109 (2007) 933-941
38. Mishra K.P., Singh V.K., Rani R., Yadav V.S., Chandran V., Srivastava S.P., and Seth P.K. Effect of lead exposure on the immune response of some occupationally exposed individuals. Toxicology 188 (2003) 251-259
39. Monnet-Tschudi F., Zurich M., Boschat C., Corbaz A., and Honegger P. Involvement of environmental mercury and lead in the etiology of neurodegenerative diseases. Rev. Environ. Health. 21 (2006) 105-117
40. Mora S., Rifai N., Buring J.E., and Ridker P.M. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation 114 5 (2006) 381-387
41. Muldoon S.B., Cauley J.A., Kuller L.H., Morrow L., Needleman H.L., Scott J., and Hooper F.J. Effects of blood lead levels on cognitive function of older women. Neuroepidemiology 15 (1996) 62-72
42. Napoli M.D., Papa F., and Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 32 (2001) 133-138
43. Nigg J.T., Knottnerus G.M., Martel M.M., Nikolas M., Cavanagh K., Karmaus W., and Rappley M.D. Low blood lead levels associated with clinically diagnosed attention-deficit/hyperactivity disorder and mediated by weak cognitive control. Biol. Psychiatry 63 (2008) 325-331
44. Nozoe T., Saeki H., and Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am. J. Surg. 182 (2001) 197-201
45. Ólafsdottir I.S., Gislason T., Thjodleifsson B., Olafsson I., Gislason D., Jögi R., and Janson C. C reactive protein levels are increased in non-allergic but not allergic asthma: a multicentre epidemiological study. Thorax 60 (2005) 451-454
46. Papanikolaou N.C., Hatzidaki E.G., Belivanis S., Tzanakakis G.N., and Tsatsakis A.M. Lead toxicity update: a brief review. Med. Sci. Monit. 11 (2005) RA329-RA336
47. Payton M., Riggs K.M., Spiro III A., Weiss S.T., and Hu H. Relations of bone and blood lead to cognitive function: the va normative aging study. Neurotoxicol. Teratol. 20 (1998) 19-27
48. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., Rifai N., Smith Jr. S.C., Taubert K., Tracy R.P., Vinicor F., and Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American heart association. Circulation 107 (2003) 499-511
49. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., and Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286 (2001) 327-334
50. Ridker P.M. C-reactive protein and prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis towards consensus. J. Am. Coll. Cardiol. 49 (2007) 2129-2138
51. Rodríguez-Iturbe B., Sindhu R.K., Quiroz Y., and Vaziri N.D. Chronic exposure to low doses of lead results in renal infiltration of immune cells, nf-κb activation, and overexpression of tubulointerstitial angiotensin II. Antioxid. Redox Signal 7 (2005) 1269-1274
52. Sadowska A.M., van Overveld F.J., Górecka D., Zdral A., Filewska M., Demkow U.A., Luyten C., Saenen E., Zielinski J., and De Backer W.A. The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. Respir. Med. 99 (2005) 241-249
53. Schaumberg D.A., Christen W.G., Buring J.E., Glynn R.J., Rifai N., and Ridker P.M. High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in women. Arch. Ophthalmol. 125 (2007) 300-305
54. Schmid M., Schneitter A., Hinterberger S., Seeber J., Reinthaller A., and Hefler L. Association of elevated C-reactive protein levels with an impaired prognosis in patients with surgically treated endometrial cancer. Obstet. Gynecol. 110 (2007) 1231-1236
55. Schwartz J., and Otto D. Lead and minor hearing impairment. Arch. Environ. Health 46 (1991) 300-305
56. Scott S.C., Goldberg M.S., and Mayo N.E. Statistical assessment of ordinal outcomes in comparative studies. J. Clin. Epidemiol. 50 (1997) 45-55
57. Seddon J.M., Gensler G., Milton R.C., Klein M.L., and Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA 291 (2004) 704-710
58. Sesso H.D., Buring J.E., Rifai N., Blake G.J., Gaziano J.M., and Ridker P.M. C-reactive protein and the risk of developing hypertension. JAMA 290 (2003) 2945-2951
59. Shankar A., Mitchell P., Rochtchina E., Tan J., and Wang J.J. Association between circulating white blood cell count and long-term incidence of age-related macular degeneration: the blue mountains eye study. Am. J. Epidemiol. 65 (2007) 375-382
60. Spittle M.A., Hoenich N.A., Handelman G.J., Adhikarla R., Homel P., and Levin N.W. Oxidative stress and inflammation in hemodialysis patients. Am. J. Kidney Dis. 38 (2001) 1408-1413
61. Stokes M.E., Davis C.S., and Koch G.G. Categorical Data Analysis Using the SAS System (2000), SAS Institute Inc., Cary, NC
62. Straub R.H. The complex role of estrogens in inflammation. Endocr. Rev. 28 (2007) 521-574
63. Struzynska L., Dabrowska-Bouta B., Koza K., and Sulkowski G. Inflammation-like glial response in lead-exposed immature rat brain. Toxicol. Sci. 95 (2007) 156-162
64. Vahter M., Akesson A., Liden C., Ceccatelli S., and Berglund. Gender differences in the disposition and toxicity of metals. Environ. Res. 104 (2007) 85-95
65. Vozarova B., Weyer C., Lindsay R.S., Pratley R.E., Bogardus C., and Tataranni P.A. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51 (2002) 455-461
66. Wright R.O., Tsaih S.W., Schwartz J., Spiro III A., McDonald K., Weiss S.T., and Hu H. Lead exposure biomarkers and mini-mental status exam scores in older men. Epidemiology 14 (2003) 713-718
67. Yücesoy B., Turhan A., Ure M., Imir T., and Karakaya A. Effects of occupational lead and cadmium exposure on some immunoregulatory cytokine levels in man. toxicology 123 (1997) 143-147